Clinical trial · Interventional
Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis
Neoadjuvant Chemotherapy With Xeloda in Combination With Paclitaxel in Gastric Cancer With Liver Metastasis
NCT01167049CI-TRIAL-00003695unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the efficacy of capecitabine combined with paclitaxel as neoadjuvant chemotherapy for gastric cancer with liver metastasis only
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CAPECITABINE | Drug | Capecitabine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CAPECITABINE
- description
- Single arm: Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);
- interventionNames
- Drug: CAPECITABINE
Primary outcomes (1)
- measure
- Tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided
- timeFrame
- 3 years from last patient enrolled
- description
- Primary Endpoint is PFS (progression free survival), tumor response will be evaluated using RECIST criteria. Survival data will be analyzed by Kaplan Meier method. 95% CI will be provided.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ambulatory males or females, aged no less than 18 years. 2. ECOG performance status: 0-1. 3. Histologically confirmed gastric adeno-carcinoma. 4. Radiologically confirmed liver metastasis without other distant metastasis. 5. No serious concomitant medical illnesses 6. Life expectancy more than 3 months 7. Be willing and able to comply with the protocol for the duration of the study 8. No Prior treatment for metastatic disease 9. Give signed informed consent Exclusion Criteria: 1. not fit for the inclusion criteria 2. not able to comply with the protocol 3. with high risks which may compromise the benefit of proposed regimen 4. Active (significant or uncontrolled) gastrointestinal bleeding
References
Publications (0)
Data not yet available
No reference posted for this study.